FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.
What happened
FDA inspected Chemco’s Miami Lakes drug manufacturing facility from August 11 to 22, 2025. The agency found inadequate equipment cleaning and no cleaning validation, inadequate identity testing of components, and quality unit oversight failures, including repeat issues from a 2022 inspection. FDA also reviewed product labels and websites and found PRO Nail FUNGUS KILLER to be an unapproved new drug and several other OTC products to be misbranded.
What FDA found
Equipment used for multiple topical drugs had visible white residue after being logged as clean, and the company had not validated cleaning to prevent cross-contamination.
21 CFR 211.67(a) and 211.67(b)The firm did not test each component lot for identity and relied on supplier certificates without establishing their reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not adequately test high-risk components for hazardous contamination.
21 CFR 211.84(d)(1) and 211.84(d)(2)The quality unit did not adequately investigate out-of-specification results or ensure written production procedures and process validation.
21 CFR 211.22PRO Nail FUNGUS KILLER is an unapproved new drug because it is labeled for use on nails, a use FDA has determined is not generally recognized as safe and effective, and no approved application is in effect.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d); section 505GSeveral products are misbranded because labels say 'made in an FDA registered facility,' which misleadingly suggests FDA approval, and HAIR PRO misleadingly highlights stem cells.
FD&C Act section 502(a), 21 U.S.C. 352(a); 21 CFR 207.77(a); 21 CFR 201.10(c)(4)
What FDA wants
FDA asks Chemco to provide comprehensive assessments and corrective action plans for cleaning, component testing, quality investigations, and process validation, and to test retained high-risk component lots or implicated finished product batches within 30 calendar days. FDA also recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC topicals from contract manufacturers
- retailers and distributors selling SPA REDI or Eternal Spirit Beauty products
- quality teams responsible for cleaning validation and supplier qualification
This is a summary. Read the original letter on fda.gov.